SCHEMBL5508182

SCHEMBL5508182

O=c1c2cc(F)ccc2nc2n1CCCC2Br

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.43
KDM4E B2RXH2 1/20 0.43
HPGD P15428 1/20 0.43
HSD17B10 Q99714 1/20 0.43
ACHE P22303 2/20 0.41
BCHE P06276 1/20 0.41
APP P05067 2/20 0.41
RAB9A P51151 1/20 0.41
CYP3A4 P08684 1/20 0.41
DPP4 P27487 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
HRH3 Q9Y5N1 1/20 0.40
AADAT Q8N5Z0 1/20 0.40
TDO2 P48775 4/20 0.40
IDO2 Q6ZQW0 3/20 0.40
IDO1 P14902 3/20 0.40
CYP2D6 P10635 2/20 0.37
KCNH2 Q12809 1/20 0.37
GHSR Q92847 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5513404 0.92 ACHE (0.46) ALDH1A1KDM4EHPGDHSD17B10ACHE
SCHEMBL5519038 0.90 RAB9A (0.42) ALDH1A1ACHEBCHERAB9ACYP3A4
SCHEMBL5511808 0.84 HRH3 (0.38) ALDH1A1KDM4EHPGDHSD17B10ACHE
SCHEMBL5511623 0.82 ACHE (0.46) ACHEBCHERAB9ACYP3A4SMN1; SMN2
SCHEMBL5506588 0.81 ACHE (0.62) ALDH1A1KDM4EHPGDHSD17B10ACHE
SCHEMBL5512927 0.76 ACHE (0.46) ALDH1A1KDM4EHPGDHSD17B10ACHE
SCHEMBL5509462 0.76 ACHE (0.42) ALDH1A1KDM4EHPGDHSD17B10ACHE
SCHEMBL28922099 0.76 ACHE (0.39) HSD17B10ACHEBCHEAPPRAB9A
SCHEMBL5508196 0.75 GAA (0.41) ACHEBCHEAPPRAB9ACYP3A4
SCHEMBL5509709 0.74 ALDH1A1 (0.70) ALDH1A1KDM4EHPGDHSD17B10ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1521583-B1 7,8,9,10-TETRAHYDRO-6H-AZEPINO, 6,7,8,9-TETRAHYDRO-PYRIDO AND 2,3-DIHYDRO-2H-PYRROLO (2,1-B)-QUINAZOLINONE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2007-01-10 EP disclosed
US-7067519-B2 7,8,9,10-tetrahydro-6H-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2H-pyrrolo[2,1-b]-quinazolinone derivatives ACTELION PHARMACEUTICALS, LTD. (CH) 2006-06-27 US disclosed
US-20050009852-A1 7 8 9 10-tetrahydro-6h-azepino, 6 7 8 9-tetrahydro-pyrido and 2 3-dihydro-2h-pyrrolo[2 1-b]-quinazolinone derivates ACTELION PHARMACEUTICALS, LTD. (CH) 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009852-A1 7 8 9 10-tetrahydro-6h-azepino, 6 7 8 9-tetrahydro-pyrido and 2 3-dihydro-2h-pyrrolo[2 1-b]-quinazolinone derivates HCRTR2, HCRTR1, NPY1R ALDH1A1 1416/4885KDM4E 848/4885HPGD 560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.